Previous 10 |
CAMBRIDGE, Mass., Dec. 04, 2020 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced it will host a live webcast providing a current corporate overview, followed by ...
BOSTON, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced Chairperson and Chief Executive Officer Tony Coles, M.D., will participate in a fireside c...
The following slide deck was published by Cerevel Therapeutics Holdings, Inc. in conjunction with this event. For further details see: Cerevel Therapeutics (CERE) Investor Presentation - Slideshow
Cerevel Therapeutics (CERE): Q3 GAAP EPS of -$7.73.Cash and cash equivalents at the end of quarter was $13M.Press Release For further details see: Cerevel Therapeutics reports Q3 results
Participants dosed in clinical trials for lead programs in schizophrenia, epilepsy, anxiety and Parkinson’s disease Debuted as publicly traded entity under symbol CERE Net proceeds of approximately $440 million raised from completed business combination transa...
BOSTON, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (NASDAQ:CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced that members of the management team will participate in three upcoming virtual investor con...
The first participants have been dosed in Cerevel Therapeutics' (CERE) all three of the clinical trials in their Phase 3 program evaluating tavapadon in patients with Parkinson’s disease. The Phase 3 program includes three 27-week, placebo-controlled, parallel-group trials designed to ...
BOSTON, Oct. 30, 2020 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (NASDAQ:CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced that the first participants have been dosed in all three of the clinical trials in th...
B usiness combination transaction with Arya Sciences Acquisition Corp II, a special purpose acquisition company sponsored by Perceptive Advisors, completed on October 27, 2020 Combined company renamed Cerevel Therapeutics Holdings , Inc. ...
News, Short Squeeze, Breakout and More Instantly...
2024-07-10 10:20:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-20 12:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
NEW YORK, NY / ACCESSWIRE / May 29, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Cerevel Therapeutics Holdings, Inc. ("Cerevel") (NASDAQ:CERE) and AbbVie, Inc. ("AbbVie") (NYSE:ABBV). Investors who purchased Cerevel and continue to holdto the present are enco...